Aug 7
|
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
|
Aug 6
|
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
|
Aug 4
|
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
|
Jun 30
|
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
|
Jun 11
|
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
|
Jun 3
|
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
|
Mar 11
|
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
|
Feb 22
|
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit?
|
Oct 9
|
Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
Oct 7
|
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
|
Jul 12
|
When Will Biofrontera Inc. (NASDAQ:BFRI) Become Profitable?
|
Jun 24
|
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
|
May 15
|
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
|
May 6
|
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
|
May 3
|
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
|
Mar 26
|
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
|
Mar 24
|
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
|
Mar 19
|
Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Call Transcript
|
Mar 19
|
Q4 2023 Biofrontera Inc Earnings Call
|
Mar 16
|
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
|